Leveraging natural killer cells for cancer immunotherapy

Steven K. Grossenbacher, Ethan G. Aguilar, William J Murphy

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Natural killer (NK) cells are potent antitumor effector cells of the innate immune system. Based on their ability to eradicate tumors in vitro and in animal models, significant enthusiasm surrounds the prospect of leveraging human NK cells as vehicles for cancer immunotherapy. While interest in manipulating the effector functions of NK cells has existed for over 30 years, there is renewed optimism for this approach today. Although T cells receive much of the clinical and preclinical attention when it comes to cancer immunotherapy, new strategies are utilizing adoptive NK-cell immunotherapy and monoclonal antibodies and engineered molecules which have been developed to specifically activate NK cells against tumors. Despite the numerous challenges associated with the preclinical and clinical development of NK cell-based therapies for cancer, NK cells possess many unique immunological properties and hold the potential to provide an effective means for cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)487-497
Number of pages11
JournalImmunotherapy
Volume9
Issue number6
DOIs
StatePublished - May 1 2017

Fingerprint

Natural Killer Cells
Immunotherapy
Neoplasms
Aptitude
Cell- and Tissue-Based Therapy
Immune System
Animal Models
Monoclonal Antibodies
T-Lymphocytes

Keywords

  • bortezomib
  • cancer stem cell
  • CAR
  • cetuximab
  • cytokines
  • immunotherapy
  • lenalidomide
  • natural killer cell
  • radiotherapy
  • rituximab
  • trastuzumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Leveraging natural killer cells for cancer immunotherapy. / Grossenbacher, Steven K.; Aguilar, Ethan G.; Murphy, William J.

In: Immunotherapy, Vol. 9, No. 6, 01.05.2017, p. 487-497.

Research output: Contribution to journalReview article

Grossenbacher, Steven K. ; Aguilar, Ethan G. ; Murphy, William J. / Leveraging natural killer cells for cancer immunotherapy. In: Immunotherapy. 2017 ; Vol. 9, No. 6. pp. 487-497.
@article{be58cd66b4db448bbd9f8c5bc0935954,
title = "Leveraging natural killer cells for cancer immunotherapy",
abstract = "Natural killer (NK) cells are potent antitumor effector cells of the innate immune system. Based on their ability to eradicate tumors in vitro and in animal models, significant enthusiasm surrounds the prospect of leveraging human NK cells as vehicles for cancer immunotherapy. While interest in manipulating the effector functions of NK cells has existed for over 30 years, there is renewed optimism for this approach today. Although T cells receive much of the clinical and preclinical attention when it comes to cancer immunotherapy, new strategies are utilizing adoptive NK-cell immunotherapy and monoclonal antibodies and engineered molecules which have been developed to specifically activate NK cells against tumors. Despite the numerous challenges associated with the preclinical and clinical development of NK cell-based therapies for cancer, NK cells possess many unique immunological properties and hold the potential to provide an effective means for cancer immunotherapy.",
keywords = "bortezomib, cancer stem cell, CAR, cetuximab, cytokines, immunotherapy, lenalidomide, natural killer cell, radiotherapy, rituximab, trastuzumab",
author = "Grossenbacher, {Steven K.} and Aguilar, {Ethan G.} and Murphy, {William J}",
year = "2017",
month = "5",
day = "1",
doi = "10.2217/imt-2017-0013",
language = "English (US)",
volume = "9",
pages = "487--497",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Leveraging natural killer cells for cancer immunotherapy

AU - Grossenbacher, Steven K.

AU - Aguilar, Ethan G.

AU - Murphy, William J

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Natural killer (NK) cells are potent antitumor effector cells of the innate immune system. Based on their ability to eradicate tumors in vitro and in animal models, significant enthusiasm surrounds the prospect of leveraging human NK cells as vehicles for cancer immunotherapy. While interest in manipulating the effector functions of NK cells has existed for over 30 years, there is renewed optimism for this approach today. Although T cells receive much of the clinical and preclinical attention when it comes to cancer immunotherapy, new strategies are utilizing adoptive NK-cell immunotherapy and monoclonal antibodies and engineered molecules which have been developed to specifically activate NK cells against tumors. Despite the numerous challenges associated with the preclinical and clinical development of NK cell-based therapies for cancer, NK cells possess many unique immunological properties and hold the potential to provide an effective means for cancer immunotherapy.

AB - Natural killer (NK) cells are potent antitumor effector cells of the innate immune system. Based on their ability to eradicate tumors in vitro and in animal models, significant enthusiasm surrounds the prospect of leveraging human NK cells as vehicles for cancer immunotherapy. While interest in manipulating the effector functions of NK cells has existed for over 30 years, there is renewed optimism for this approach today. Although T cells receive much of the clinical and preclinical attention when it comes to cancer immunotherapy, new strategies are utilizing adoptive NK-cell immunotherapy and monoclonal antibodies and engineered molecules which have been developed to specifically activate NK cells against tumors. Despite the numerous challenges associated with the preclinical and clinical development of NK cell-based therapies for cancer, NK cells possess many unique immunological properties and hold the potential to provide an effective means for cancer immunotherapy.

KW - bortezomib

KW - cancer stem cell

KW - CAR

KW - cetuximab

KW - cytokines

KW - immunotherapy

KW - lenalidomide

KW - natural killer cell

KW - radiotherapy

KW - rituximab

KW - trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=85019021292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019021292&partnerID=8YFLogxK

U2 - 10.2217/imt-2017-0013

DO - 10.2217/imt-2017-0013

M3 - Review article

C2 - 28472904

AN - SCOPUS:85019021292

VL - 9

SP - 487

EP - 497

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 6

ER -